RELA and diffuse large B-cell lymphoma: Therefore, our current study in both patient samples and DLBCL cell lines provided additional insights into the putative roles of NF-κB p65 in immune regulation, DLBCL cell proliferation, and viability maintenance, and the utility of p65 as a biomarker to stratify DLBCL patients to receive alternative therapeutic regimens including agents targeting NF-κB [52].